Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc (NY: BHC )

5.960 -0.010 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Aug 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,136,305
Open 5.960
Bid (Size) 5.840 (1)
Ask (Size) 6.040 (1)
Prev. Close 5.970
Today's Range 5.920 - 6.040
52wk Range 3.960 - 11.46
Shares Outstanding 358,808,755
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Bausch Health Solvency Remains A Concerns, Analyst Downgrades Stock
Bausch Health reports Q2 2024 GAAP EPS of $0.03, missing the consensus of $0.28. Revenue hits $2.403 billion, up 11% YoY. Piper Sandler downgrades BHC to Underweight with a price target of $3, citing... 
Via Benzinga

Performance

YTD
-23.39%
-23.39%
1 Month
+0.17%
+0.17%
3 Month
-3.87%
-3.87%
6 Month
-35.08%
-35.08%
1 Year
-27.85%
-27.85%

More News

Read More
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Via Benzinga
Bausch Health Announces Second Quarter 2024 Results
Via ACCESSWIRE
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
Via Benzinga
BHC Stock Plunges as Bausch Health Appears on the Brink of Bankruptcy
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Why Bausch health Shares Are Falling Today
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Bausch Health Responds to Market Rumors
Via ACCESSWIRE
Bausch Health Welcomes Two New Members to the Executive Leadership Team
Via ACCESSWIRE
Bausch Health Announces 2024 Annual Meeting of Shareholder Results
Via ACCESSWIRE
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Stocks Plummet After Tech Earnings, Manufacturing Data
Via Talk Markets
Topics Stocks
Exposures US Equities
Why Bausch Health Companies Shares Are Falling After Q1 Results
Via Benzinga
Bausch Health Announces First Quarter 2024 Results
Via ACCESSWIRE
Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024
Via ACCESSWIRE
Bausch Health Brings Patent Infringement Lawsuit Against Norwich Pharmaceuticals
Via ACCESSWIRE
Bausch Health Reports Promising R&D Trial Updates on Amiselimod and Scientific Data Presented at International Healthcare Conferences
Via ACCESSWIRE
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Via ACCESSWIRE
Bausch Health Announces Updates Related to Norwich XIFAXAN Matters
Via ACCESSWIRE
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Via ACCESSWIRE
Why Bausch Health Companies Stock Dived by More Than 7% Today
Via The Motley Fool
BHC Stock Earnings: Bausch Health Companies Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Bausch Health to Announce First-Quarter 2024 Results on May 2
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.